EEI-BIOTECHFINANCES Eléments Essentiels d'Information / Essential Elements of Information
Friday, March 29th 2019 at 7:15pm UTC First-ever Results to be Presented from Multiple Studies Evaluating Company’s PNK Allogeneic Cell Therapy in Patients with Acute Myeloid Leukemia and Multiple Myeloma WARREN, N.J.–(BUSINESS WIRE)– Celularity, Inc. (“Celularity” or the “Company”), a clinical-stage cell therapeutics company developing allogeneic cellular therapies harnessed from …
Plus »Preliminary Data from Phase 1 Study Evaluating ADXS-NEO Suggest Rapid Immunogenicity and Clinical Activity
Friday, March 29th 2019 at 7:00pm UTC Data to be Presented at AACR Annual Meeting PRINCETON, N.J.–(BUSINESS WIRE)– Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of ADXS-NEO data in a poster discussion entitled “Safety and Immunogenicity of …
Plus »Definiens et Ultivue annoncent une collaboration visant à développer des offres conjointes dans le domaine de l’immunofluorescence multiplexe et de l’analyse d’image numérique par intelligence artificielle
Friday, March 29th 2019 at 6:03pm UTC CAMBRIDGE, Massachusetts–(BUSINESS WIRE)– Ultivue, un développeur de tests d’identification et de quantification des biomarqueurs tissulaires destinés aux laboratoires de recherche translationnelle et en pathologie, et Definiens, une société pionnière de l’analyse des images basée sur l’intelligence artificielle, ont annoncé aujourd’hui une collaboration visant …
Plus »Definiens and Ultivue Announce a Collaboration to Co-Develop Joint Offerings in Multiplexed Immunofluorescence (IF) and AI Enabled Digital Image Analysis
Friday, March 29th 2019 at 3:11pm UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– Ultivue, a developer of tissue biomarker identification and quantification assays for translational and pathology research labs, and Definiens, a pioneer in artificial intelligence (AI) based image analysis, today announced a collaboration to expand Definiens standardized IO-Panel capabilities to IF. The …
Plus »CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study
Friday, March 29th 2019 at 1:00pm UTC VIENNA, Va.–(BUSINESS WIRE)– CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company’s pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) has completed its recent review of the …
Plus »Seattle Genetics Completes Enrollment in Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
Friday, March 29th 2019 at 12:00pm UTC -Phase 2 innovaTV 204 Trial Designed to Support Potential Accelerated Approval Pathway in U.S.- BOTHELL, Wash.–(BUSINESS WIRE)– Seattle Genetics, Inc. (Nasdaq:SGEN) today announced completion of enrollment in the potentially pivotal innovaTV 204 phase 2 clinical trial evaluating the efficacy, safety and tolerability of …
Plus »Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics
Friday, March 29th 2019 at 12:00pm UTC New molecular platform to access intracellular targets across a broad range of tumor cell types Opens up new range of therapeutic opportunities for difficult-to-treat cancers INGELHEIM, Germany & BERLIN–(BUSINESS WIRE)– Boehringer Ingelheim today announced that it acquired ICD Therapeutics. The acquisition includes rights …
Plus »bluebird bio Receives Positive Opinion from CHMP for ZYNTEGLO™ (autologous CD34+ cells encoding ?A-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent ?-Thalassemia (TDT) Who Do Not Have ?0/?0 Genotype
Friday, March 29th 2019 at 11:44am UTC First gene therapy recommended for approval in the EU for TDT Treatment with ZYNTEGLO has been shown to help eliminate the need for chronic blood transfusions in patients with TDT ZYNTEGLO is bluebird bio’s first gene therapy submitted for regulatory approval CAMBRIDGE, Mass.–(BUSINESS …
Plus »Dicerna™ Announces the Presentation of Updated Data Demonstrating Utility of its Lead Compound DCR-PHXC in Treating Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2)
Friday, March 29th 2019 at 10:30am UTC —PHYOX™1 Investigators Reported Potent, Durable Response in Phase 1 Study in Patients with PH1 and PH2 at German Society of Pediatric Nephrology 50th Annual Meeting— —Company Announces Initiation of Participant Screening for PHYOX2 Pivotal Trial in PH1 and PH2— CAMBRIDGE, Mass.–(BUSINESS WIRE)– Dicerna™ …
Plus »Applied DNA Announces Exclusive Cannabis Licensing and Cooperation Agreement with Theracann International
Friday, March 29th 2019 at 9:30am UTC – Applied DNA to Receive Staged Payments Totaling $5M Over the Next Four-Months – – Agreement Calls for Annual Payment Minima that Scale from $7 Million in Year 3 to $20 Million in Year 15 – – Applied DNA Technology to Power ETCH …
Plus »
